BR0314270A - Ativação de miostatina com metaloprotease e processos de modulação da atividade da miostatina - Google Patents

Ativação de miostatina com metaloprotease e processos de modulação da atividade da miostatina

Info

Publication number
BR0314270A
BR0314270A BR0314270-1A BR0314270A BR0314270A BR 0314270 A BR0314270 A BR 0314270A BR 0314270 A BR0314270 A BR 0314270A BR 0314270 A BR0314270 A BR 0314270A
Authority
BR
Brazil
Prior art keywords
myostatin
metalloprotease
activation
agent
decreasing
Prior art date
Application number
BR0314270-1A
Other languages
English (en)
Inventor
Se-Jin Lee
Alexandra C Mcpherron
Daniel S Greenspan
William N Pappano
Neil M Wolfman
Kathy Tomkinson
Original Assignee
Univ Johns Hopkins
Wisconsin Alumni Res Found
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins, Wisconsin Alumni Res Found, Wyeth Corp filed Critical Univ Johns Hopkins
Publication of BR0314270A publication Critical patent/BR0314270A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

"ATIVAçãO DE MIOSTATINA COM METALOPROTEASE E PROCESSOS DE MODULAçãO DA ATIVIDADE DA MIOSTATINA". Foi determinado que a clivagem pela metaloprotease de um pró-peptídeo da miostatina resulta na ativação de uma miostatina latente inativa a uma forma ativa. Conseq³entemente, são fornecidos métodos de identificação de agentes que modulam a ativação da miostatina mediada pela metaloprotease, pois são agentes identificados que usam tais métodos. Também são fornecidos métodos de modulação de crescimento muscular em um organismo pelo aumento ou pela diminuição da clivagem mediada pela metaloprotease de um pró-peptídeo da miostatina.
BR0314270-1A 2002-09-16 2003-09-16 Ativação de miostatina com metaloprotease e processos de modulação da atividade da miostatina BR0314270A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41113302P 2002-09-16 2002-09-16
US43916403P 2003-01-09 2003-01-09
US48686303P 2003-07-10 2003-07-10
PCT/US2003/029079 WO2004024890A2 (en) 2002-09-16 2003-09-16 Metalloprotease activation of myostatin, and methods of modulating myostatin activity

Publications (1)

Publication Number Publication Date
BR0314270A true BR0314270A (pt) 2005-08-02

Family

ID=31999236

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0314380-5A BR0314380A (pt) 2002-09-16 2003-09-16 Ativação de metaloprotease de miostatina e métodos de modulação da atividade de miostatina
BR0314270-1A BR0314270A (pt) 2002-09-16 2003-09-16 Ativação de miostatina com metaloprotease e processos de modulação da atividade da miostatina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR0314380-5A BR0314380A (pt) 2002-09-16 2003-09-16 Ativação de metaloprotease de miostatina e métodos de modulação da atividade de miostatina

Country Status (12)

Country Link
US (3) US7572599B2 (pt)
EP (3) EP1549747A4 (pt)
JP (3) JP4547561B2 (pt)
AT (1) ATE461275T1 (pt)
AU (3) AU2003267246A1 (pt)
BR (2) BR0314380A (pt)
CA (2) CA2496213C (pt)
DE (1) DE60331778D1 (pt)
ES (1) ES2344734T3 (pt)
IL (1) IL166651A (pt)
MX (2) MXPA05002648A (pt)
WO (2) WO2004024890A2 (pt)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200526779A (en) * 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
US7320789B2 (en) * 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US7572763B2 (en) * 2002-02-21 2009-08-11 Wyeth Follistatin domain containing proteins
EP1572909A4 (en) * 2002-02-21 2007-06-06 Wyeth Corp PROTEIN CONTAINING A DOMAINE OF FOLLISTATIN
US20090035260A1 (en) * 2002-07-29 2009-02-05 Therapicon Srl Enhanced nasal composition of active peptide
DE60331778D1 (de) * 2002-09-16 2010-04-29 Univ Johns Hopkins Metalloproteaseaktivierung von myostatin und verfahren zur modulation der myostatinaktivität
AR047392A1 (es) 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
UA85055C2 (ru) 2003-06-02 2008-12-25 Уайт Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний
ITMI20040235A1 (it) * 2004-02-13 2004-05-13 Therapicon Srl Preparazione farmaceutica per il cavo orale
JP5335239B2 (ja) 2004-09-30 2013-11-06 マイオスティン・セラピューティクス・プロプライエタリー・リミテッド ミオスタチンアイソフォーム
NZ538097A (en) * 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
MX2007011405A (es) * 2005-03-23 2007-10-11 Wyeth Corp Deteccion de una respuesta inmune para agentes moduladores de crecimiento y la diferenciacion del factor 8 (gdf 8).
JP2008537488A (ja) * 2005-03-23 2008-09-18 ワイス Ｇｄｆ−８モジュレート物質の検出
JP5052517B2 (ja) * 2005-10-06 2012-10-17 イーライ リリー アンド カンパニー 抗ミオスタチン抗体
UA92504C2 (en) * 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
US20090163579A1 (en) * 2005-10-14 2009-06-25 Daniel Raederstorff Novel use of nutraceutical compositions
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
EP1880731A1 (en) * 2006-07-18 2008-01-23 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Human growth and differentiation factor GDF-5
AU2012200193B2 (en) * 2006-07-21 2015-04-09 Genera Istrazivanja D.O.O. BMP-1 procollagen C-proteinase for diagnosis and treatment of bone and soft tissue defects and disorders
CA2829865A1 (en) 2006-07-21 2008-01-24 Genera Istrazivanja D.O.O. Bmp-1 procollagen c-proteinase for diagnosis and treatment of bone and soft tissue defects and disorders
CN101522707B (zh) * 2006-08-03 2013-08-28 莫约斯汀医疗有限公司 肌肉生长抑制素拮抗剂
EA015916B1 (ru) * 2006-09-05 2011-12-30 Эли Лилли Энд Компани Моноклональные антитела к миостатину и их применения
MX369784B (es) 2007-09-26 2019-11-21 Chugai Pharmaceutical Co Ltd Metodo de modificacion del punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
DK2708559T3 (en) 2008-04-11 2018-06-14 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of repeatedly binding two or more antigen molecules
ES2358028B1 (es) * 2009-10-19 2011-11-28 Universidade De Santiago De Compostela Procedimiento de obtención de catalizadores híbridos compuestos por complejos de metales de transición encapsulados en nanopartículas porosas de sílice, titania o circonia.
CN108715614A (zh) 2010-11-30 2018-10-30 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
PL2880053T3 (pl) 2012-08-01 2021-01-11 Ikaika Therapeutics, Llc Łagodzenie uszkodzenia tkanek i włóknienia przez przeciwciało przeciwko ltbp4
CA2882272C (en) 2012-08-24 2023-08-29 Chugai Seiyaku Kabushiki Kaisha Fc.gamma.riib-specific fc region variant
EP3597747B1 (en) 2012-08-24 2023-03-15 Chugai Seiyaku Kabushiki Kaisha Mouse fcgammarii-specific fc antibody
WO2014062535A1 (en) 2012-10-15 2014-04-24 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
WO2014144458A1 (en) 2013-03-15 2014-09-18 Abbott Laboratories Methods of maintaining and improving muscle function
AU2014250434B2 (en) 2013-04-02 2019-08-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
RS61778B1 (sr) 2013-05-06 2021-06-30 Scholar Rock Inc Kompozicije i postupci za modulaciju faktora rasta
KR20160106684A (ko) 2014-01-10 2016-09-12 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 히드록시포름아미드 유도체 및 그의 용도
TWI593967B (zh) * 2014-05-01 2017-08-01 高雄醫學大學 二級抗體所辨識之抗原決定位及其用途
CA3005158A1 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
JP6227191B1 (ja) * 2014-12-19 2017-11-08 中外製薬株式会社 抗ミオスタチン抗体、変異Ｆｃ領域を含むポリペプチド、および使用方法
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
EP3922645A1 (en) 2015-09-15 2021-12-15 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
WO2017075037A1 (en) * 2015-10-27 2017-05-04 Scholar Rock, Inc. Primed growth factors and uses thereof
JP7141336B2 (ja) 2015-12-25 2022-09-22 中外製薬株式会社 抗ミオスタチン抗体および使用方法
WO2017120523A2 (en) 2016-01-08 2017-07-13 Scholar Rock, Inc. Anti-pro/latent myostatin antibodies and methods of use thereof
SI3368069T1 (sl) 2016-06-13 2021-03-31 Scholar Rock, Inc. Uporaba zaviralcev miostatina in kombinirane terapije
JP6527643B2 (ja) 2016-08-05 2019-06-05 中外製薬株式会社 Ｉｌ−８関連疾患の治療用又は予防用組成物
EP4218817A3 (en) 2017-01-06 2023-09-06 Scholar Rock, Inc. Methods for treating metabolic diseases by inhibiting myostatin activation
AU2019406214A1 (en) 2018-12-21 2021-08-05 Northwestern University Use of annexins in preventing and treating muscle membrane injury
US20220062299A1 (en) 2018-12-26 2022-03-03 Northwestern University Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
WO2021060884A1 (ko) * 2019-09-24 2021-04-01 마이오텍사이언스 주식회사 비천연 아미노산 유도체를 함유하는 근감소증의 예방 또는 치료용 약학적 조성물

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2591227B1 (fr) * 1985-12-06 1988-11-10 Pasteur Institut Peptides capables d'inhiber les interactions entre les virus lav et les lymphocytes t4, produits qui en sont derives et leurs applications
US6162896A (en) * 1991-05-10 2000-12-19 The Salk Institute For Biological Studies Recombinant vertebrate activin receptors
US7393682B1 (en) * 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
US5994618A (en) * 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
CA2157577C (en) * 1993-03-19 2009-11-17 Se-Jin Lee Growth differentiation factor-8
EP1378572B1 (en) * 1993-05-12 2006-10-25 Genetics Institute, LLC Bmp-11 compositions
DE69434739T2 (de) * 1993-08-26 2007-05-10 Genetics Institute, LLC, Cambridge Menschliche Knochen-morphogenetische Proteine zur Verwendung bei neuronaler Rehgeneration
US5914234A (en) * 1994-07-08 1999-06-22 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-11
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US6696260B1 (en) * 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
US6656475B1 (en) * 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US6891082B2 (en) * 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6369201B1 (en) * 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
US6004937A (en) * 1998-03-09 1999-12-21 Genetics Institute, Inc. Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]
WO1999056768A1 (en) * 1998-05-06 1999-11-11 Metamorphix, Inc. Methods for treating diabetes by inhibiting gdf-8
TW200526779A (en) * 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
US7320789B2 (en) * 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
EP1572909A4 (en) * 2002-02-21 2007-06-06 Wyeth Corp PROTEIN CONTAINING A DOMAINE OF FOLLISTATIN
US7572763B2 (en) * 2002-02-21 2009-08-11 Wyeth Follistatin domain containing proteins
DE60331778D1 (de) * 2002-09-16 2010-04-29 Univ Johns Hopkins Metalloproteaseaktivierung von myostatin und verfahren zur modulation der myostatinaktivität
AR047392A1 (es) * 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
KR101304718B1 (ko) * 2002-12-20 2013-09-05 암겐 인코포레이티드 미오스타틴을 저해하는 결합제
JP2005042091A (ja) * 2003-07-04 2005-02-17 Nitto Denko Corp 電気絶縁材料用ポリイミド樹脂

Also Published As

Publication number Publication date
MXPA05002968A (es) 2005-09-08
WO2004024092A3 (en) 2004-08-26
CA2496213A1 (en) 2004-03-25
BR0314380A (pt) 2005-07-19
AU2010201977A1 (en) 2010-06-03
US20040138118A1 (en) 2004-07-15
ATE461275T1 (de) 2010-04-15
CA2496213C (en) 2013-11-19
DE60331778D1 (de) 2010-04-29
JP5369044B2 (ja) 2013-12-18
US20060275280A1 (en) 2006-12-07
JP4547561B2 (ja) 2010-09-22
EP1578928B1 (en) 2010-03-17
EP1549747A4 (en) 2006-08-23
EP1578928A2 (en) 2005-09-28
EP1578928A4 (en) 2007-01-03
JP2010248195A (ja) 2010-11-04
AU2003267246A1 (en) 2004-04-30
US7572599B2 (en) 2009-08-11
JP2006507356A (ja) 2006-03-02
CA2498044A1 (en) 2004-03-25
WO2004024092A2 (en) 2004-03-25
ES2344734T3 (es) 2010-09-06
MXPA05002648A (es) 2005-08-19
WO2004024890A3 (en) 2006-07-27
AU2003272394A1 (en) 2004-04-30
US20050043232A1 (en) 2005-02-24
EP1549747A2 (en) 2005-07-06
WO2004024890A2 (en) 2004-03-25
IL166651A0 (en) 2006-01-15
JP2006517525A (ja) 2006-07-27
IL166651A (en) 2013-12-31
EP2192129A1 (en) 2010-06-02

Similar Documents

Publication Publication Date Title
BR0314270A (pt) Ativação de miostatina com metaloprotease e processos de modulação da atividade da miostatina
ATE247173T1 (de) Charakterisierung von polypeptiden
ATE460429T1 (de) Polypeptide enthaltend extrazellulären domäne von il-20ra und/oderr il-20rb
PT948541E (pt) Analogos da pthrp
DK0960127T3 (da) Isoleret dimert fibroblastaktiverende protein-alfa og anvendelser deraf
ES2079481T3 (es) Un procedimiento para la determinacion de la actividad funcional de la proteina s o de la proteina c libre en una muestra de plasma.
HUP0301795A2 (hu) Emberi D-G szerinproteázt kódoló DNS
DE69831500D1 (de) Humane checkpointkinase, hcds1, zusammensetzungen und verfahren
DE69700561D1 (de) Verfahren zur Entfernung von N-Terminalem Methionin
DE60134230D1 (de) Substraten und nachweise zur wirksamkeit von beta-secretase
DK1353948T3 (da) Oplöselige biologiske analoge til bata-amyloidpeptid
DE60140493D1 (de) Verfahren zur Reinigung stark anionischer Proteine
HUP0001458A2 (hu) Specifikus hasnyálmirigy lipáz inhibitor hatású peptidek, ezeket tartalmazó gyógyszerkészítmények és diagnosztikai reagensek, valamint ezek alkalmazása
AU2002345804A1 (en) Antimicrobially active peptide
DE69712878T2 (de) Phosphatasemodulator
BR0114977A (pt) segmentos preferidos de proteìna de filamento neural e métodos para uso dos mesmos
PT640098E (pt) Gene de coronavirus canino e suas utilizacoesc
ATE390440T1 (de) Neuroaktive peptide
DK0769025T3 (da) Metoder og sammensætninger i relation til proteoglycanproteiner til diagnosticering af brusknedbrydning
ATE228362T1 (de) Verwendung eines retinoidids zur in vivo erhöhung der entkopplung des ucp2 proteins
ES2103482T3 (es) Antigeno de linfocitos t citotoxicos utilizado como inhibidor de la cisteina proteasa.
WO2002055707A3 (en) Cloning of an inhibitor of antigen-receptor signaling by a retroviral-based functional screen
ATE471343T1 (de) Neues rfrp-3 und dna dafür
WO2001067097A3 (en) Method of identifying modulators of presenilin
ES2172214T3 (es) Procedimiento de identificacion de una imagen o de un documento.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2112 DE 28/06/2011.